1-isopropyl-2,2-bis(4-methoxyphenyl)ethylenediamine | 201611-56-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-isopropyl-2,2-bis(4-methoxyphenyl)ethylenediamine
• 英文别名: DAIPEN；1,1-bis(p-methoxyphenyl)-2-isopropyl-1,2-diaminoethane；1,1-bis(4-methoxyphenyl)-3-methyl-1,2-butanediamine；1-isopropyl-2,2-di(p-methoxyphenyl)ethylenediamine；1,1-Bis(4-methoxyphenyl)-3-methylbutane-1,2-diamine
• CAS: 201611-56-5
• 化学式: C₁₉H₂₆N₂O₂
• 分子量: 314.428
• InChiKey: WDYGPMAMBXJESZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  70.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH PHOSPHINO-OXIDE BASED RUTHENIUM COMPLEXES
  申请人：Saudan Lionel

  公开号：US20110190523A1

  公开（公告）日：2011-08-04

  The present invention relates to the field of catalytic hydrogenation and, more particularly, to the use of specific ruthenium catalysts or pre-catalysts in hydrogenation processes for the reduction of ketones, aldehydes, esters or lactones into their corresponding alcohols or diols respectively. The preferred catalysts are ruthenium complexes comprising a ligand of the type (N—N) type and a ligand of the type (P—PO).

  本发明涉及催化加氢领域，更具体地涉及在加氢过程中使用特定的钌催化剂或前驱体，用于将酮、醛、酯或内酯还原为相应的醇或二醇。首选催化剂是包含(N—N)型配体和(P—PO)型配体的钌配合物。
• METHOD FOR CONVERTING HYDROXYL GROUP OF ALCOHOL
  申请人：Takasago International Corporation

  公开号：US20210047254A1

  公开（公告）日：2021-02-18

  The present invention relates to: a method for converting a hydroxyl group of an alcohol; and a catalyst which makes the method possible. A method for converting a hydroxyl group of an alcohol according to the present invention is characterized by producing a compound represented by CH(R 1 )(R 2 )Nu (wherein R 1 , R 2 and Nu are as defined below) by reacting an alcohol represented by CH(R 1 )(R 2 )OH (wherein each of R 1 and R 2 represents a hydrogen atom, an optionally substituted alkyl group, or the like) and a compound having an active proton, which is represented by H-Nu (wherein Nu represents a group represented by —CHX 1 -EWG 1 or —NR 3 R 4 ; X 1 represents a hydrogen atom or the like; EWG 1 represents an electron-withdrawing group; and each of R 3 and R 4 represents a hydrogen atom, an optionally substituted alkyl group, or the like), with each other in the presence of a complex of a group 7-11 metal of the periodic table and at least one solid base that is selected from the group consisting of layered double hydroxides, composite oxides and calcium hydroxide.

  本发明涉及：将醇的羟基转化为的方法；以及使该方法成为可能的催化剂。根据本发明的将醇的羟基转化为的方法的特征在于，在周期表的7-11族金属群的复合物存在下，通过将一个由CH(R1)(R2)OH（其中R1和R2分别表示氢原子、可选择取代的烷基基团或类似物）表示的醇与一个具有活性质子的化合物（其中Nu表示由—CHX1-EWG1或—NR3R4表示的基团；X1表示氢原子或类似物；EWG1表示电子吸引基团；R3和R4分别表示氢原子、可选择取代的烷基基团或类似物）反应，从而产生一个由CH(R1)(R2)Nu（其中R1、R2和Nu如下定义）表示的化合物。同时，所述反应中至少选择一种来自层状双氢氧化物、复合氧化物和氢氧化钙的固体碱作为催化剂。
• SELECTIVE HYDROGENATION OF ALDEHYDE WITH RU/BIDENTATE LIGANDS COMPLEXES
  申请人：FIRMENICH SA

  公开号：US20140243526A1

  公开（公告）日：2014-08-28

  The present invention relates to processes for the reduction by hydrogenation, using molecular H 2 , of a C 5 -C 20 substrate containing one or two aldehydes functional groups into the corresponding alcohol or diol, characterized in that said process is carried out in the presence of —at least one catalyst or pre-catalyst in the form of a ruthenium complex having a coordination sphere of the N 2 P 2 O 2 , wherein the coordinating atoms N 2 are provided by a first bidentate ligand, the coordinating atoms P 2 are provided by a second bidentate ligand and the coordinating atoms O 2 are provided by two non-linear carboxylate ligands; and —optionally of an acidic additive.

  本发明涉及利用分子H2对含有一个或两个醛基官能团的C5-C20底物进行加氢还原的过程，将其转化为相应的醇或二醇，其特征在于所述过程在以下条件下进行：—至少一种催化剂或前驱体存在，其形式为具有N2P2O2配位球的钌配合物，其中配位原子N2由第一双齿配体提供，配位原子P2由第二双齿配体提供，配位原子O2由两个非线性羧酸盐配体提供；和—可选地加入酸性添加剂。
• [EN] TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE EN TANT QU'INHIBITEURS DE KINASE PIM
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2012154274A1

  公开（公告）日：2012-11-15

  Compounds of Formula I: in which R1, R2, R3, R4 and R10 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.

  式I的化合物：其中R1、R2、R3、R4和R10的含义如规范中所述，在通过PIM-1和/或PIM-2和/或PIM-3激酶介导的疾病治疗中有用的受体酪氨酸激酶抑制剂。
• [EN] METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION<br/>[FR] PROCÉDÉS ET INTERMÉDIAIRES POUR PRÉPARER UN COMPOSÉ THÉRAPEUTIQUE UTILE DANS LE TRAITEMENT D'UNE INFECTION VIRALE PAR RETROVIRIDAE
  申请人：GILEAD SCIENCES INC

  公开号：WO2019161280A1

  公开（公告）日：2019-08-22

  The present disclosure relates to methods and intermediates useful for preparing a compound of formula (I): (I) or a co-crystal, solvate, salt or combination thereof.

  本公开涉及用于制备化合物(I)的方法和中间体，该化合物的结构如下：(I)，或其共晶体、溶剂合物、盐或其组合物。